RPRX
Royalty Pharma Plc
NASDAQ: RPRX · HEALTHCARE · BIOTECHNOLOGY
$54.87
-0.76% today
Updated 2026-06-12
Market cap
$31.60B
P/E ratio
28.88
P/S ratio
12.95x
EPS (TTM)
$1.90
Dividend yield
1.62%
52W range
$34 – $57
Volume
3.6M
WallStSmart proprietary scores
65
out of 100
Grade: B
Buy
Investment rating
6.0
Growth
B5.0
Quality
C+8.0
Profitability
A4.0
Valuation
C2/9
Piotroski F-Score
Weak
1.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$59.25
+7.98%
12-Month target
$45.61
-16.88%
Intrinsic (DCF)
$34.38
Margin of safety
-59.60%
3 Strong Buy6 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 33.90% — above average
+ Free cash flow $760.54M — positive
+ Revenue growth 11.00% QoQ
Risks
- Piotroski 2/9 — weak financial health
- Altman Z 1.15 — distress zone
- 59.60% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $2.24B | $2.35B | $2.26B | $2.38B | $2.44B | $3.4B |
| Net income | $42.83M | $1.13B | $858.98M | $770.95M | $295.00M | — |
| EPS | — | — | — | — | $1.90 | $5.29 |
| Free cash flow | $102.83M | $872.28M | $2.77B | $2.49B | $760.54M | — |
| Profit margin | 1.91% | 48.20% | 37.95% | 32.42% | 33.90% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-05 | WEATHERMAN, ELIZABETH H | Buy | 4,545 | — |
| 2026-06-05 | NORDEN, GREGORY | Buy | 4,545 | — |
| 2026-06-05 | LOVE, TED W | Buy | 4,545 | — |
Peer comparison
Smart narrative
Royalty Pharma Plc trades at $54.87. representing a P/E of 28.88x trailing earnings. Our Smart Value Score of 65/100 indicates the stock is good. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 1.15, it sits in the distress. TTM revenue stands at $2.44B. with profit margins at 33.90%. Our DCF model estimates intrinsic value at $34.38.
Frequently asked questions
What is Royalty Pharma Plc's stock price?
Royalty Pharma Plc (RPRX) trades at $54.87, on a P/E of 28.9x and a P/S of 13.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Royalty Pharma Plc overvalued?
Royalty Pharma Plc carries a Smart Value Score of 65/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $34.38 against the $54.87 price, so on cash flow terms the market is paying a premium for Royalty Pharma Plc's growth. The Buy rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Royalty Pharma Plc (RPRX)?
The 12-month analyst consensus target is $59.25, about 8.0% above the current $54.87. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of RPRX by 2030?
Our research-backed model puts the 2030 base case at $76.76, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Royalty Pharma Plc (RPRX)?
Our DCF model estimates intrinsic value at $34.38, a -59.6% margin of safety versus today's $54.87. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Royalty Pharma Plc's revenue?
Royalty Pharma Plc's trailing twelve-month revenue is $2.44B, and our model projects it reaching about $5.70B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Royalty Pharma Plc's Altman Z-Score is 1.15, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio12.95x
ROE12.01%
Beta0.42
50D MA$51.52
200D MA$42.99
Shares out0.44B
Float0.41B
Short ratio—
Avg volume3.6M
Performance
1 week+0.00%
1 month+4.11%
3 months+20.53%
YTD+42.39%
1 year—
3 years—
5 years—